GET DAILY SIGNALSWhy Is Veradermics (MANE) Stock Down -12.81% Today?
Key Takeaways
- MANE shares fell about 12.81% to roughly $136.50 in Thursday trading, retreating from the prior session's record close of $156.56.
- The pullback follows a parabolic rally that left the stock up more than 370% year to date and trading at an all-time high.
- Profit-taking is the primary driver, amplified by insider-selling headlines including a Form 144 filing on proposed share sales.
- A "data vacuum" weighs on sentiment — the next major clinical catalyst (female Study 306) is not expected until the first half of 2027.
- Broader small-cap biotech momentum cooled as recently extended names consolidated.
- Traders are watching whether the stock holds technical support near $143 and $137.
- For deeper analysis of this ticker, explore our Price Targets, Earnings, and Forecast pages.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Opening Summary
Veradermics, Incorporated (MANE) is a New Haven, Connecticut-based, dermatologist-founded late clinical-stage biopharmaceutical company developing VDPHL01, an oral extended-release minoxidil candidate for pattern hair loss in men and women. On Thursday, MANE shares fell 12.81% to about $136.50, down from a previous close of $156.56, giving back a portion of the sharp gains that had carried the stock to a record high. Markets attributed the move primarily to profit-taking after an extended rally, alongside fresh signs of insider selling and a stretch of relatively quiet clinical news ahead.
Profit-Taking After a Parabolic Rally
The decline comes on the heels of a dramatic run-up. MANE has climbed from a 52-week low of $32 to more than $156, a roughly five-fold move, powered by a string of positive clinical readouts for VDPHL01 — including 12-month data from Study 302 and positive Phase 3 Study 304 results. With the male-pattern hair loss story now largely priced in, momentum traders and longer-term holders alike began locking in gains, triggering the sell-off. In fast-moving, low-float biotech names, such reversals can be sharp once buyers step back.
Insider Selling and Form 144 Filings
Adding to the supply overhang, a Form 144 filing surfaced indicating a proposed sale of securities, following a period in which insiders reportedly sold roughly $103 million worth of MANE stock over the prior quarter, including sales by executives and directors. Insider distribution into a fresh all-time high is not unusual after a major rally, but it can weigh on investor psychology, particularly when it coincides with an absence of near-term clinical catalysts.
The "Data Vacuum" — Catalyst Gap Until 2027
Investors are also recalibrating the near-term story. The headline-grabbing male program data has been delivered, and the next significant de-risking event — topline results from Study 306 in female pattern hair loss — is not expected until the first half of 2027. That leaves a multi-month window with no scheduled pivotal readout, making it harder for a valuation of more than $6 billion, with no product revenue, to sustain extended upside.
Market Context and Trading Activity
The pullback unfolded against a backdrop of cooling momentum across high-flying small-cap biotech names, which had surged in recent weeks. MANE shares traded well off their highs as selling pressure built, with activity consistent with distribution rather than a single headline-driven crash. The decline also pushed the stock back through recently watched technical levels; analysts had flagged the $143 prior-high close and the $137 late-October breakout zone as key areas of support, with a decisive close above the $152.82 high required to sustain the breakout.
What Comes Next for MANE
Looking ahead, the focus shifts to execution and the company's regulatory pathway. Veradermics has said it expects to report topline data from the female-pattern hair loss Study 306 in the first half of 2027, which will be the next major value-inflecting event. Investors will also monitor any updates on FDA engagement and a potential New Drug Application filing for VDPHL01. On the financial side, the company ended September with roughly $798 million in cash and marketable securities and has said it expects its runway to extend into 2030, providing balance-sheet stability even as losses continue. Risks include the inherent uncertainty of clinical trials, the gap until the next data readout, and continued insider supply.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. The featured robots represent those currently outperforming, providing a focused view of what quantitative systems are doing right now. Explore the Trending AI Robots page to see which strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for MANE turns positive, indicating new upward trend
MANE saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator turned positive. In 14 of the 14 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MANE just turned positive on November 10, 2026. Looking at past instances where MANE's MACD turned positive, the stock continued to rise in 7 of 7 cases over the following month. The odds of a continued upward trend are 90%.
MANE moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MANE advanced for three days, in 42 of 47 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 26 of 28 cases where MANE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MANE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
MANE broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.127) is normal, around the industry mean (3.498). P/E Ratio (-55.597) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MANE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MANE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement